A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

NCT04035226 · clinicaltrials.gov ↗
COMPLETED
Status
254
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Janssen-Cilag Ltd.

Collaborators